iQure Obtains Japanese Patent Related to Cataplasmazyme

[Asia Economy Reporter Oh Ju-yeon] iCure announced on the 27th that it has acquired a Japanese patent for a transdermal ultraviolet-curable hydrogel resin, hydrogel, and a cataplasma containing these. The company stated, "It is manufactured using a non-toxic solvent and can contain a large amount of moisture, minimizing skin irritation. Additionally, by controlling the degree of crosslinking, adhesion and elasticity can be easily adjusted," adding, "By adjusting the crosslinking degree, drug release properties and transdermal absorption control are possible, providing a cataplasma with excellent skin permeability and transdermal absorption rate." Furthermore, the company added, "It is easy to manufacture, stable even after long-term storage, and after hydrogel crosslinking, it can be immediately cut and packaged without separate aging or cooling processes, making it economical and commercially viable."

This content was produced with the assistance of AI translation services.